|Bid||26.86 x 3000|
|Ask||27.19 x 1200|
|Day's Range||26.83 - 27.10|
|52 Week Range||15.92 - 28.17|
|Beta (5Y Monthly)||1.52|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.25|
Subscribe to Yahoo Finance Plus to view Fair Value for XENTLearn more
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
An increase in Intersect ENT's (XENT) operating costs puts pressure on its Q3 bottom line.
Intersect ENT (XENT) delivered earnings and revenue surprises of -14.29% and -17.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?